Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Rommie Amaro
University of California, San Diego, Department: Chemistry
Should you be removed from our database? Contact us at [email protected]. Read more below.
Actavalon, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Amaro is the co-founder of Actavalon, Inc., a member of the Scientific Advisory Board and holds (b)(4) equity interest. The company’s mission is to apply computational, biological and chemical approaches to seek small molecule p53 reactivators with broad activity against p53 mutant cancer cells. This project is to collect data from research laboratories in the pharmaceutical industry and universities and organize them in an electronic database which will be publicly available for advancing the state of the art in computer-aid drug design.
AN OPEN RESOURCE TO ADVANCE COMPUTER-AIDED DRUG DESIGN
Computers are used to help design new drugs, and there is great promise for computational methods to become even more precise and effective than they are today. However, creating improved methods will require giving computational scientists access to many more experimental measurements of the properties of drugs and drug-like molecules than are now available, so that advanced methods can be tested and optimized. The present project will meet this need, and thus ultimately speed the discovery of new medications, by collecting the required data from research laboratories in the pharmaceutical industry and universities and organizing them in an electronic database so they can be easily accessed and used.
Filed on December 15, 2014.
Tell us what you know about Rommie Amaro's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Rommie Amaro filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Rommie Amaro | University of California, San Diego | Conflict of Interest | Actavalon, Inc. | $350,000 - $399,999 |
| Rommie Amaro | University of California, San Diego | Conflict of Interest | Actavalon | $350,000 - $399,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.